Back to School: How biopharma can reboot drug development. Access exclusive analysis here
A retrospective review of cardiovascular events in a 75-patient cohort from an open-label, dose-escalation,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury